4.6 Article

Endoscopic submucosal dissection vs. endoscopic mucosal resection for early Barrett's neoplasia in the West: a retrospective study

Journal

ENDOSCOPY
Volume 54, Issue 5, Pages 439-446

Publisher

GEORG THIEME VERLAG KG
DOI: 10.1055/a-1541-7659

Keywords

-

Ask authors/readers for more resources

The study compared the outcomes of endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) for early Barrett's esophagus neoplasia, finding that ESD had higher en bloc and R0 resection rates, lower recurrence/residual disease rates, and less need for repeat endoscopic treatments compared to EMR.
Background The difference in clinical outcomes after endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) for early Barrett's esophagus (BE) neoplasia remains unclear. We compared the recurrence/residual tissue rates, resection outcomes, and adverse events after ESD and EMR for early BE neoplasia. Methods We included patients who underwent EMR or ESD for BE-associated high grade dysplasia (HGD) or T1a esophageal adenocarcinoma (EAC) at eight academic hospitals. We compared demographic, procedural, and histologic characteristics, and follow-up data. A time-to-event analysis was performed to evaluate recurrence/residual disease and a Kaplan-Meier curve was used to compare the groups. Results 243 patients (150 EMR; 93 ESD) were included. EMR had lower en bloc (43% vs. 89%; P <0.001) and R0 (56% vs. 73%; P =0.01) rates than ESD. There was no difference in the rates of perforation (0.7% vs. 0; P >0.99), early bleeding (0.7% vs. 1%; P >0.99), delayed bleeding (3.3% vs. 2.1%; P =0.71), and stricture (10% vs. 16%; P =0.16) between EMR and ESD. Patients with non-curative resections who underwent further therapy were excluded from the recurrence analysis. Recurrent/residual disease was 31.4% [44/140] for EMR and 3.5% [3/85] for ESD during a median (interquartile range) follow-up of 15.5 (6.75-30) and 8 (2-18) months, respectively. Recurrence-/residual disease-free survival was significantly higher in the ESD group. More patients required additional endoscopic resection procedures to treat recurrent/residual disease after EMR (EMR 24.2% vs. ESD 3.5%; P <0.001). Conclusions ESD is safe and results in more definitive treatment of early BE neoplasia, with significantly lower recurrence/residual disease rates and less need for repeat endoscopic treatments than with EMR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available